249 related articles for article (PubMed ID: 34829729)
1. Tumor-Associated Mast Cells in Urothelial Bladder Cancer: Optimizing Immuno-Oncology.
Choi HW; Naskar M; Seo HK; Lee HW
Biomedicines; 2021 Oct; 9(11):. PubMed ID: 34829729
[TBL] [Abstract][Full Text] [Related]
2. Immune escape mechanisms and immunotherapy of urothelial bladder cancer.
Yang Z; Xu Y; Bi Y; Zhang N; Wang H; Xing T; Bai S; Shen Z; Naz F; Zhang Z; Yin L; Shi M; Wang L; Wang L; Wang S; Xu L; Su X; Wu S; Yu C
J Clin Transl Res; 2021 Aug; 7(4):485-500. PubMed ID: 34541363
[TBL] [Abstract][Full Text] [Related]
3. Focus on mast cells in the tumor microenvironment: Current knowledge and future directions.
Shi S; Ye L; Yu X; Jin K; Wu W
Biochim Biophys Acta Rev Cancer; 2023 Jan; 1878(1):188845. PubMed ID: 36476563
[TBL] [Abstract][Full Text] [Related]
4. Mast cells: A double-edged sword in cancer.
Derakhshani A; Vahidian F; Alihasanzadeh M; Mokhtarzadeh A; Lotfi Nezhad P; Baradaran B
Immunol Lett; 2019 May; 209():28-35. PubMed ID: 30905824
[TBL] [Abstract][Full Text] [Related]
5. Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy.
Cheng W; Fu D; Xu F; Zhang Z
Oncogenesis; 2018 Jan; 7(1):2. PubMed ID: 29358573
[TBL] [Abstract][Full Text] [Related]
6. The roles of mast cells in anticancer immunity.
Dalton DK; Noelle RJ
Cancer Immunol Immunother; 2012 Sep; 61(9):1511-20. PubMed ID: 22527244
[TBL] [Abstract][Full Text] [Related]
7. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
8. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
9. Immune Profiling Reveals Molecular Classification and Characteristic in Urothelial Bladder Cancer.
Yang L; Li A; Liu F; Zhao Q; Ji S; Zhu W; Yu W; Zhang R; Liu Y; Li W; Zhang Y
Front Cell Dev Biol; 2021; 9():596484. PubMed ID: 33777927
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy With Bacillus Calmette-Guerin (BCG) in a 16-Year-Old With Urothelial Bladder Carcinoma.
Martinez-Thomas JM; Galicia-Belaunzaran LF; Merayo-Chalico CE; Palatchi J; Angulo-Lozano JC
Cureus; 2022 May; 14(5):e24994. PubMed ID: 35719797
[TBL] [Abstract][Full Text] [Related]
11. The anti-tumor effect of intravesical administration of normal urothelial cells on bladder cancer.
Huang CP; Chen CC; Shyr CR
Cytotherapy; 2017 Oct; 19(10):1233-1245. PubMed ID: 28818454
[TBL] [Abstract][Full Text] [Related]
12. Frenemies in the Microenvironment: Harnessing Mast Cells for Cancer Immunotherapy.
Sulsenti R; Jachetti E
Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376140
[TBL] [Abstract][Full Text] [Related]
13. Mast Cell-Tumor Interactions: Molecular Mechanisms of Recruitment, Intratumoral Communication and Potential Therapeutic Targets for Tumor Growth.
Segura-Villalobos D; Ramírez-Moreno IG; Martínez-Aguilar M; Ibarra-Sánchez A; Muñoz-Bello JO; Anaya-Rubio I; Padilla A; Macías-Silva M; Lizano M; González-Espinosa C
Cells; 2022 Jan; 11(3):. PubMed ID: 35159157
[TBL] [Abstract][Full Text] [Related]
14. The Role of Mast Cells in Molding the Tumor Microenvironment.
Rigoni A; Colombo MP; Pucillo C
Cancer Microenviron; 2015 Dec; 8(3):167-76. PubMed ID: 25194694
[TBL] [Abstract][Full Text] [Related]
15. Modifying the Non-muscle Invasive Bladder Cancer Immune Microenvironment for Optimal Therapeutic Response.
Annels NE; Simpson GR; Pandha H
Front Oncol; 2020; 10():175. PubMed ID: 32133299
[TBL] [Abstract][Full Text] [Related]
16. IL33 and Mast Cells-The Key Regulators of Immune Responses in Gastrointestinal Cancers?
Eissmann MF; Buchert M; Ernst M
Front Immunol; 2020; 11():1389. PubMed ID: 32719677
[TBL] [Abstract][Full Text] [Related]
17. Effect of TLR4 and B7-H1 on immune escape of urothelial bladder cancer and its clinical significance.
Wang YH; Cao YW; Yang XC; Niu HT; Sun LJ; Wang XS; Liu J
Asian Pac J Cancer Prev; 2014; 15(3):1321-6. PubMed ID: 24606459
[TBL] [Abstract][Full Text] [Related]
18. Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies.
Wang Y; Yang M; Yu Q; Yu L; Shao S; Wang X
Expert Rev Anticancer Ther; 2015 Jan; 15(1):85-93. PubMed ID: 25231670
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy in the Treatment of Urothelial Bladder Cancer: Insights From Single-Cell Analysis.
Zang J; Ye K; Fei Y; Zhang R; Chen H; Zhuang G
Front Oncol; 2021; 11():696716. PubMed ID: 34123863
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients.
Liu X; Yao D; Liu C; Cao Y; Yang Q; Sun Z; Liu D
Tumour Biol; 2016 Jun; 37(6):8367-74. PubMed ID: 26733163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
